Inozyme Property Plant And Equipment Gross from 2010 to 2024

INZY Stock  USD 2.72  0.07  2.64%   
Inozyme Pharma Property Plant And Equipment Gross yearly trend continues to be fairly stable with very little volatility. Property Plant And Equipment Gross will likely drop to about 4.2 M in 2024. During the period from 2010 to 2024, Inozyme Pharma Property Plant And Equipment Gross regression line of annual values had r-squared of  0.64 and arithmetic mean of  1,779,397. View All Fundamentals
 
Property Plant And Equipment Gross  
First Reported
2010-12-31
Previous Quarter
M
Current Value
4.2 M
Quarterly Volatility
2.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.65. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Property Plant And Equipment Gross Growth Pattern

Below is the plot of the Property Plant And Equipment Gross of Inozyme Pharma over the last few years. It is Inozyme Pharma's Property Plant And Equipment Gross historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
Property Plant And Equipment Gross10 Years Trend
Slightly volatile
   Property Plant And Equipment Gross   
       Timeline  

Inozyme Property Plant And Equipment Gross Regression Statistics

Arithmetic Mean1,779,397
Geometric Mean899,830
Coefficient Of Variation118.13
Mean Deviation1,828,530
Median408,000
Standard Deviation2,102,058
Sample Variance4.4T
Range5M
R-Value0.80
Mean Square Error1.7T
R-Squared0.64
Significance0.0003
Slope376,531
Total Sum of Squares61.9T

Inozyme Property Plant And Equipment Gross History

20244.2 M
2023M
20225.4 M
20215.4 M
20202.6 M

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Property Plant And Equipment Gross, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Property Plant And Equipment GrossM4.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.